Prostate cancer clinical trials of the Southwest Oncology Group

E. David Crawford, Edward P. Deantoni, Maha Hussain, Ian M. Thompson, Charles A. Coltman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its early years, SWOG prostate cancer trials now cover the entire spectrum of the disease: localized, locally advanced, metastatic and hormone-refractory disease. As the world's largest GU cancer research group, the GU committee of SWOG has pioneered studies in combined androgen therapy for metastatic disease, quality-of-life (QOL) assessments for patients with localized and advanced disease, adjuvant therapy models, and prostate cancer chemoprevention. The committee has also formed the GU Global Group, whose purpose is to convene the chairs of the GU committees of all the major national and international oncology cooperative groups. Meeting semiannually, this group discusses activities within their respective organizations, plans collaborative strategies and protocols, and establishes global strategy in prostate cancer clinical research. The future directions of national and international prostate cancer trials will build on this broad foundation of well-conceived, logically sequenced studies.

Original languageEnglish (US)
Pages (from-to)1154-1163
Number of pages10
JournalOncology
Volume11
Issue number8
StatePublished - 1997

Fingerprint

Prostatic Neoplasms
Clinical Trials
Urogenital Neoplasms
Research
Hormones
Group Processes
Chemoprevention
Androgens
Quality of Life
Organizations
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

David Crawford, E., Deantoni, E. P., Hussain, M., Thompson, I. M., & Coltman, C. A. (1997). Prostate cancer clinical trials of the Southwest Oncology Group. Oncology, 11(8), 1154-1163.

Prostate cancer clinical trials of the Southwest Oncology Group. / David Crawford, E.; Deantoni, Edward P.; Hussain, Maha; Thompson, Ian M.; Coltman, Charles A.

In: Oncology, Vol. 11, No. 8, 1997, p. 1154-1163.

Research output: Contribution to journalArticle

David Crawford, E, Deantoni, EP, Hussain, M, Thompson, IM & Coltman, CA 1997, 'Prostate cancer clinical trials of the Southwest Oncology Group', Oncology, vol. 11, no. 8, pp. 1154-1163.
David Crawford E, Deantoni EP, Hussain M, Thompson IM, Coltman CA. Prostate cancer clinical trials of the Southwest Oncology Group. Oncology. 1997;11(8):1154-1163.
David Crawford, E. ; Deantoni, Edward P. ; Hussain, Maha ; Thompson, Ian M. ; Coltman, Charles A. / Prostate cancer clinical trials of the Southwest Oncology Group. In: Oncology. 1997 ; Vol. 11, No. 8. pp. 1154-1163.
@article{a3ddbe89bb574d1aab5229c02badc15e,
title = "Prostate cancer clinical trials of the Southwest Oncology Group",
abstract = "The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its early years, SWOG prostate cancer trials now cover the entire spectrum of the disease: localized, locally advanced, metastatic and hormone-refractory disease. As the world's largest GU cancer research group, the GU committee of SWOG has pioneered studies in combined androgen therapy for metastatic disease, quality-of-life (QOL) assessments for patients with localized and advanced disease, adjuvant therapy models, and prostate cancer chemoprevention. The committee has also formed the GU Global Group, whose purpose is to convene the chairs of the GU committees of all the major national and international oncology cooperative groups. Meeting semiannually, this group discusses activities within their respective organizations, plans collaborative strategies and protocols, and establishes global strategy in prostate cancer clinical research. The future directions of national and international prostate cancer trials will build on this broad foundation of well-conceived, logically sequenced studies.",
author = "{David Crawford}, E. and Deantoni, {Edward P.} and Maha Hussain and Thompson, {Ian M.} and Coltman, {Charles A.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "1154--1163",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Prostate cancer clinical trials of the Southwest Oncology Group

AU - David Crawford, E.

AU - Deantoni, Edward P.

AU - Hussain, Maha

AU - Thompson, Ian M.

AU - Coltman, Charles A.

PY - 1997

Y1 - 1997

N2 - The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its early years, SWOG prostate cancer trials now cover the entire spectrum of the disease: localized, locally advanced, metastatic and hormone-refractory disease. As the world's largest GU cancer research group, the GU committee of SWOG has pioneered studies in combined androgen therapy for metastatic disease, quality-of-life (QOL) assessments for patients with localized and advanced disease, adjuvant therapy models, and prostate cancer chemoprevention. The committee has also formed the GU Global Group, whose purpose is to convene the chairs of the GU committees of all the major national and international oncology cooperative groups. Meeting semiannually, this group discusses activities within their respective organizations, plans collaborative strategies and protocols, and establishes global strategy in prostate cancer clinical research. The future directions of national and international prostate cancer trials will build on this broad foundation of well-conceived, logically sequenced studies.

AB - The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its early years, SWOG prostate cancer trials now cover the entire spectrum of the disease: localized, locally advanced, metastatic and hormone-refractory disease. As the world's largest GU cancer research group, the GU committee of SWOG has pioneered studies in combined androgen therapy for metastatic disease, quality-of-life (QOL) assessments for patients with localized and advanced disease, adjuvant therapy models, and prostate cancer chemoprevention. The committee has also formed the GU Global Group, whose purpose is to convene the chairs of the GU committees of all the major national and international oncology cooperative groups. Meeting semiannually, this group discusses activities within their respective organizations, plans collaborative strategies and protocols, and establishes global strategy in prostate cancer clinical research. The future directions of national and international prostate cancer trials will build on this broad foundation of well-conceived, logically sequenced studies.

UR - http://www.scopus.com/inward/record.url?scp=12644259504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644259504&partnerID=8YFLogxK

M3 - Article

C2 - 9268978

AN - SCOPUS:12644259504

VL - 11

SP - 1154

EP - 1163

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 8

ER -